-
Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China
•
Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares in SanReno Therapeutics, a Shanghai-based developer of kidney drugs. This move is aimed at bolstering Novartis’s kidney product portfolio in China. The financial details of the transaction have not been disclosed. SanReno Therapeutics was established…
